Department of Brain Health News
The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
Dr. Jeffrey Cummings examines drug pipeline for treatments, and finds reason for optimism.
A collection of news stories featuring the people and programs of UNLV.
The Chambers-Grundy Center for Transformative Neuroscience will advance research and the science of treatment for Alzheimer’s and other neurological disorders.
Now's the time for those working in the field to pursue post-professional doctorate to be ready for expanded job market once economy gears back up.
A collection of news stories capturing the excitement and accomplishments of UNLV at the start of a new decade.
A collection of news stories from 2019 highlighting UNLV's impact in Southern Nevada and beyond.
Brain Health In The News
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism.
A systematic review of Alzheimer disease (AD) treatments currently in development demonstrate the progressive emphasis on nonamyloid targets, including candidate treatments addressing for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions.
Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer's disease clinical trials, led a five-year review of all Alzheimer's drugs in the development pipeline. He says today there is more hope than ever that we'll one day solve Alzheimer's.
Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we’ll one day solve Alzheimer’s.
